Literature DB >> 10712319

Assessment of bronchodilator responsiveness in infants with bronchiolitis. A comparison of the tidal and the raised volume rapid thoracoabdominal compression technique.

M Modl1, E Eber, E Weinhandl, W Gruber, M S Zach.   

Abstract

Whether bronchodilators should be used for the treatment of infants with bronchiolitis is subject to debate, partly because of the low sensitivity of the methods for assessing lung function changes in infants. In the present study, we compared the recently introduced raised volume (RVRTC) with the conventional end-tidal rapid thoracoabdominal compression (ETRTC) technique in infants with acute viral bronchiolitis. In 17 infants lung function was assessed by both methods, at baseline values and after salbutamol inhalation. Forced expiratory volumes (FEV(0.5), FEV(0.75), FEV(1.0)) were used for the quantification of RVRTC measurement, and maximal expiratory flow at functional residual capacity (Vmax (FRC)) for ETRTC measurements. A significant individual change was defined by a mean postbronchodilator value that differed from baseline value by more than twice the within-subject coefficient of variation (CV). Group mean intrasubject CVs ranged from 4.7% to 5.3% for FEV parameters; it was 14.0% for Vmax (FRC). For the group, post-bronchodilator measurements did not differ significantly from baseline measurements. For the majority of infants, however, the within-subject comparison of responses revealed substantial differences between both techniques; while no infant demonstrated a significant increase in Vmax (FRC), eight (47%) infants responded with significantly improved timed volumes. The RVRTC technique provides the investigator with a more sensitive diagnostic tool for documenting the effectiveness of therapeutic interventions on an individual basis. Furthermore, the findings of the present study provide a rationale for the application of bronchodilators in a subgroup of infants with acute bronchiolitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712319     DOI: 10.1164/ajrccm.161.3.9812063

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  7 in total

1.  Bronchodilator responsiveness in wheezy infants and toddlers is not associated with asthma risk factors.

Authors:  Jason Debley; Sanja Stanojevic; Amy G Filbrun; Padmaja Subbarao
Journal:  Pediatr Pulmonol       Date:  2011-10-17

2.  [Recurring obstructive bronchitis and asthmatic bronchitis in preschool aged children].

Authors:  Manfred Götz; Ernst Eber; Thomas Frischer; Elisabeth Horak; Herbert Kurz; Josef Riedler; Rudolf Schmitzberger; Maximilian Zach
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 3.  Beta2-agonists for asthma: the pediatric perspective.

Authors:  Padmaja Subbarao; Felix Ratjen
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

4.  Bronchodilation in infants with malacia or recurrent wheeze.

Authors:  W Hofhuis; E C van der Wiel; H A W M Tiddens; G Brinkhorst; W P J Holland; J C de Jongste; P J F M Merkus
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

5.  Nasal versus oronasal raised volume forced expirations in infants--a real physiologic challenge.

Authors:  Mohy G Morris
Journal:  Pediatr Pulmonol       Date:  2012-02-10

6.  Atopy, cytokine production, and airway reactivity as predictors of pre-school asthma and airway responsiveness.

Authors:  Edgar E Sarria; Rita Mattiello; Weiguo Yao; Valentina Chakr; Christina J Tiller; Jeffrey Kisling; Rebeka Tabbey; Zhangsheng Yu; Mark H Kaplan; Robert S Tepper
Journal:  Pediatr Pulmonol       Date:  2013-02-08

7.  Low cord-serum 25-hydroxyvitamin D levels are associated with poor lung function performance and increased respiratory infection in infancy.

Authors:  Shen-Hao Lai; Sui-Ling Liao; Ming-Han Tsai; Man-Chin Hua; Chih-Yung Chiu; Kuo-Wei Yeh; Tsung-Chieh Yao; Jing-Long Huang
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.